CXCL10 and ulcerative colitis: Furthermore, clinical-grade fully human anti-CXCL10 monoclonal antibodies, such as MDX-1100 (eldelumab), have already been developed and tested in Phase II clinical trials for rheumatoid arthritis and ulcerative colitis [193].